ROCKstar Phase II Trial of Daily or Twice-Daily Belumosudil (KD025) in Previously Treated Patients With Chronic GVHD

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
In patients with cGVHD after alloSCT and 2-5 prior lines of systemic therapy, belumosudil was well tolerated with response rates > 70% and a median DoR of 50 weeks.
Format: Microsoft PowerPoint (.ppt)
File Size: 289 KB
Released: December 14, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Related Content

Downloadable slideset with the latest clinical trial data on BTK inhibitors in frontline and relapsed/refractory CLL, from Clinical Care Options (CCO)

Jeff P. Sharman, MD Released: May 7, 2021

Downloadable slideset with pharmacist considerations for the management of CLL using BTK inhibitors, from Clinical Care Options (CCO)

Emily Bucholtz Headshot Emily Bucholtz, RPh Released: May 7, 2021

Downloadable slideset from Sagar Lonial, MD and Kathryn Maples, PharmD, BCOP on treatment options for patients with R/R myeloma, from Clinical Care Options (CCO).

Sagar Lonial, MD Kathryn Maples, PharmD, BCOP Released: May 4, 2021

Pharmacist’s perspective on improving management of CLL by discussing treatment options with patients, from Clinical Care Options (CCO)

Emily Bucholtz Headshot Emily Bucholtz, RPh Released: April 29, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue